Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Halb, L; Amann, BJ; Bornemann-Cimenti, H.
[Use of intracutaneous or subcutaneous botulinum toxin for postherpetic neuralgia].
Nervenarzt. 2017; 88(4):408-414 Doi: 10.1007/s00115-016-0250-6 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Leading authors Med Uni Graz
Bornemann-Cimenti Helmar
Sampl Larissa
Co-authors Med Uni Graz
Amann Benjamin Joachim
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Botulinum neurotoxin (BoNT), a toxin of the anaerobic spore-forming bacterium Clostridium botulinum is used as a drug for alleviating muscle spasticity. Other indications include the cosmetic application in facial muscles, hyperhidrosis and neurogenic bladder disorders. It has been approved since 2010 as the first prophylactic treatment for chronic migraine. The analgesic effect of BoNT was observed early on and is currently the subject of intensive research. Painful postherpetic neuralgia is a common complication of an infection with herpes zoster virus. Despite modern treatment algorithms and medication, satisfactory pain treatment is not achieved in all patients. The use of BoNT could represent a new treatment option. The aim of this article is to provide an overview of the current evidence for the use of BoNT for postherpetic neuralgia. We conducted a systematic literature search with the keywords "botulinum" and "neuropathic" and included original articles in which BoNT was used subcutaneously or intradermally for the treatment of postherpetic neuralgia. The initial search yielded 212 results. After a title and abstract screening, the number was reduced to 11 relevant publications (5 case reports or series and 6 prospective studies). The results in the currently available literature show that BoNT is an effective therapeutic option for postherpetic neuralgia. In all studies, a significant effect on the pain and also on relevant patient-oriented secondary variables, such as the quality of life and especially the quality of sleep was shown. The only reported side effect was pain during administration.
Find related publications in this database (using NLM MeSH Indexing)
Administration, Cutaneous -
Botulinum Toxins - administration & dosage
Botulinum Toxins - adverse effects
Dose-Response Relationship, Drug -
Drug Monitoring - methods
Evidence-Based Medicine -
Humans -
Injections, Intradermal -
Injections, Subcutaneous -
Neuralgia, Postherpetic - diagnosis
Neuralgia, Postherpetic - drug therapy
Pain - chemically induced
Pain - prevention & control
Treatment Outcome -

© Med Uni GrazImprint